论文部分内容阅读
目的探讨阿托伐他汀治疗冠心病高脂血症的临床疗效。方法选取2013年10月—2015年9月海安县肿瘤医院收治的冠心病高脂血症患者952例,按照随机数字表法分为对照组与研究组,各476例。对照组给予阿司匹林等常规药物治疗,研究组在对照组基础上给予阿托伐他汀治疗,观察两组患者临床疗效、血脂水平〔胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平〕、血清炎性因子水平〔肿瘤坏死因子-α(TNF-α)、基质金属蛋白酶-9(MMP-9)、C反应蛋白(CRP)水平〕及药物不良反应发生情况。结果研究组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前两组患者TC、TG、LDL-C、HDL-C水平比较,差异无统计学意义(P>0.05);治疗后研究组TC、TG、LDL-C低于对照组,HDL-C高于对照组,差异有统计学意义(P<0.05)。治疗前两组患者TNF-α、MMP-9、CRP水平比较,差异无统计学意义(P>0.05);治疗后研究组患者TNF-α、MMP-9、CRP低于对照组,差异有统计学意义(P<0.05)。研究组患者不良反应发生率高于对照组,差异有统计学意义(P<0.05)。结论阿托伐他汀治疗冠心病高脂血症的临床疗效确切,可有效改善患者血脂水平,抑制血清炎性因子,缓解动脉粥样硬化。
Objective To investigate the clinical efficacy of atorvastatin in the treatment of coronary heart disease with hyperlipidemia. Methods 952 patients with coronary heart disease and hyperlipidemia admitted to Cancer Hospital of Hai’an from October 2013 to September 2015 were divided into control group and research group according to random number table method, 476 cases each. The control group was treated with aspirin and other conventional drugs. The study group was given atorvastatin on the basis of the control group. The clinical curative effect, blood lipid level (TC, triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) levels), serum levels of inflammatory cytokines [tumor necrosis factor-α (TNF-α), matrix metalloproteinase-9 (CRP) levels] and adverse drug reactions. Results The total effective rate of the study group was higher than that of the control group, the difference was statistically significant (P <0.05). The levels of TC, TG, LDL-C and HDL-C in the two groups before treatment were not significantly different (P> 0.05). After treatment, the levels of TC, TG and LDL-C in the study group were lower than those in the control group In the control group, the difference was statistically significant (P <0.05). There was no significant difference in TNF-α, MMP-9 and CRP levels between the two groups before treatment (P> 0.05). After treatment, the levels of TNF-α, MMP-9 and CRP in the study group were lower than those in the control group Significance (P <0.05). The incidence of adverse reactions in study group was higher than that in control group, the difference was statistically significant (P <0.05). Conclusions Atorvastatin is effective in treating coronary heart disease with hyperlipidemia, which can effectively improve blood lipid level, inhibit serum inflammatory factors and relieve atherosclerosis.